Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)

Q: What does CUSIP 03836J201 represent in this 13F holders report?

CUSIP 03836J201 is the security identifier for APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share in Q1 2024?

22 institutional investors reported APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 03836J201

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class: Equity / Common stock, par value $0.001 per share
Shares outstanding: 9,144,889
Total 13F shares: 1,624,394
Share change: +697,614
Total reported value: $10,764,195
Price per share: $6.69
Number of holders: 22
Value change: +$4,966,764
Number of buys: 12
Number of sells: 6

Security key

03836J201

Report period

Q1 2024

Institutions

Top holders

APRE full security history Newer quarter: Q2 2024 Previous quarter: Q4 2023 Aprea Therapeutics, Inc. SEC filings Aprea Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 03836J201

Newer quarter: Q2 2024 Previous quarter: Q4 2023

Recent filing periods:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
AIGH Capital Management LLC	13F	Company	3.8%	349,300	$1,641,710	—	31 Dec 2023	13F
Sio Capital Management, LLC	13F	Company	3.1%	280,000	$1,316,000	—	31 Dec 2023	13F
Worth Venture Partners, LLC	13F	Company	0.95%	87,169	$409,694	—	31 Dec 2023	13F
Walleye Capital LLC	13F	Company	0.87%	80,000	$376,000	—	31 Dec 2023	13F
ROYAL BANK OF CANADA	13F	Company	0.48%	44,025	$207,000	—	31 Dec 2023	13F
VANGUARD GROUP INC	13F	Company	0.38%	34,688	$163,034	—	31 Dec 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.19%	17,473	$82,150	—	31 Dec 2023	13F
MORGAN STANLEY	13F	Company	0.19%	17,218	$80,925	—	31 Dec 2023	13F
BlackRock Finance, Inc.	13F	Company	0.09%	8,504	$39,969	—	31 Dec 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.04%	3,251	$15,280	—	31 Dec 2023	13F
GROUP ONE TRADING LLC	13F	Company	0.02%	2,160	$10,152	—	31 Dec 2023	13F
PNC FINANCIAL SERVICES GROUP, INC.	13F	Company	0.01%	1,000	$4,700	—	31 Dec 2023	13F
MB, LEVIS & ASSOCIATES, LLC	13F	Company	0.01%	806	$3,788	—	31 Dec 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	548	$2,576	—	31 Dec 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	272	$1,278	—	31 Dec 2023	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	200	$940	—	31 Dec 2023	13F
WealthCollab, LLC	13F	Company	0%	158	$743	—	31 Dec 2023	13F
JPMORGAN CHASE & CO	13F	Company	0%	5	$24	—	31 Dec 2023	13F
Princeton Global Asset Management LLC	13F	Company	0%	100	$470	—	31 Dec 2023	13F
UBS Group AG	13F	Company	0%	3	$14	—	31 Dec 2023	13F
Christian S. Schade	3/4/5	Director	— mixed-class rows	312,846 mixed-class rows	$976,345	—	28 Jul 2022	3/4/5
Scott M. Coiante	3/4/5	SVP, Chief Financial Officer	— mixed-class rows	234,265 mixed-class rows	$533,970	—	28 Jul 2022	3/4/5
Eyal C. Attar	3/4/5	SVP, Chief Medical Officer, Director	— class O/S missing	57,392	$211,254	—	03 Jun 2022	3/4/5
Gregory Alan Korbel	3/4/5	SVP, Chief Operating Officer	— mixed-class rows	81,462 mixed-class rows	$168,445	—	28 Jul 2022	3/4/5
Lars B. Abrahmsen	3/4/5	SVP, Chief Scientific Officer	— mixed-class rows	143,700 mixed-class rows	$160,855	—	10 Mar 2022	3/4/5
Fouad Namouni	3/4/5	Director	— mixed-class rows	27,360 mixed-class rows	$16,969	—	30 Jun 2021	3/4/5
Michael Aaron Kelly	3/4/5	Director	— mixed-class rows	27,360 mixed-class rows	$16,969	—	30 Jun 2021	3/4/5

Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q1 2024

As of 31 Mar 2024, Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by 22 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,624,394 shares. The largest 10 holders included AIGH Capital Management LLC, Sio Capital Management, LLC, SPHERA FUNDS MANAGEMENT LTD., Nantahala Capital Management, LLC, DAFNA Capital Management LLC, VANGUARD GROUP INC, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, HighTower Advisors, LLC, and BlackRock Inc.. This page lists 22 institutional shareholders reporting positions in this security for the Q1 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders

Q1 2024 holders

Holder diff

Investor	Q4 2023 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q4 2023 Value $	Q1 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.